ClinicaliQ Trial Snapshot
- Low-dose Interleukin-2 After Myocardial Infarction to Investigate Effects on Tissue-resident Regulatory T Cells — Recruiting • Non-phase study • Cardiology / Cardiovascular • NCT07610538.
- What is being tested: Low-dose interleukin-2 (ld-IL-2) administration in post-myocardial infarction patients to determine its effects on tissue-resident regulatory T cells (Tregs), assessed through advanced single-cell RNA sequencing analysis of gene signatures related to activation, proliferation, and immune suppressive function across different….
- Patient eligibility overview: The trial enrolls patients who have experienced myocardial infarction and are suitable candidates for ld-IL-2 treatment, with comparisons made between treatment and control groups stratified by individual tissue beds to evaluate tissue-specific responses.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The primary goals of this study are to compare the differences in tissue-resident Treg gene signature for activation, proliferation, and suppressive function using single-cell/-nucleus RNA sequencing in patients treated with ld-IL-2 compared to control grouped by individual tissue beds from in and around the heart. Additionally, tissue-resident Tregs will be compared to peripheral blood Tregs from the same patient to assess the differential effect of ld-IL-2 on the two compartments.
Eligibility Snapshot
- : * Aged over 18 years old * Undergoing CABG surgery
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.